Article Abstract

What is the impact of dose modification in adjuvant chemotherapy for ovarian cancer?

Authors: Tharani Sivakumaran, Linda Mileshkin

Abstract

Ovarian cancer is the eight most common cancer occurring in women worldwide (1). The cornerstone of management of advanced epithelial ovarian cancer (EOC) and primary peritoneal carcinoma (PPC) involves primary debulking surgery followed by adjuvant chemotherapy or neoadjuvant chemotherapy followed by interval cytoreduction (2,3). The chemotherapy backbone remains as carboplatin and paclitaxel.